^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATA3219

    i
    Other names: ATA3219
    Company:
    Atara
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    16d
    ATA3219-NHL-103: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=40, Recruiting, Atara Biotherapeutics | Initiation date: Jan 2024 --> Sep 2024
    Trial initiation date • CAR T-Cell Therapy
    |
    ATA3219
    4ms
    ATA3219-AEC-104: A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=52, Not yet recruiting, Atara Biotherapeutics | N=26 --> 52
    Enrollment change • CAR T-Cell Therapy
    |
    ATA3219
    7ms
    A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Lupus Nephritis (clinicaltrials.gov)
    P1, N=26, Not yet recruiting, Atara Biotherapeutics
    New P1 trial • CAR T-Cell Therapy
    |
    ATA3219
    10ms
    A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=40, Recruiting, Atara Biotherapeutics
    New P1 trial
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    ATA3219
    2years
    Optimization and Characterization of ATA3219: A Novel and Potent Allogeneic CD19-CAR T Therapy without Gene-Editing (TCT-ASTCT-CIBMTR 2023)
    This updated preclinical dataset for ATA3219 demonstrates the flexibility of our EBV T-cell manufacturing process through improvements in the polyfunctional phenotype, potent expansion and targeting against B cell tumors with low alloreactivity. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    ATA3219
    almost4years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219
    almost4years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219
    almost4years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219
    almost4years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219
    almost4years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing (TCT-ASTCT-CIBMTR 2021)
    Conclusions This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrates persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219
    4years
    [VIRTUAL] ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19-CAR T Therapy without the Need for Gene-Editing (ASH 2020)
    CONCLUSIONS This preclinical dataset for CD19-1XX CAR+ EBV T cells demonstrate, persistence, polyfunctional phenotype and efficient targeting of CD19-expressing tumor cells, both in vitro and in vivo, with limited allocytoxicity against antigen-negative, HLA-mismatched targets. These findings support advancing ATA3219 to clinical evaluation.
    IO biomarker
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    ATA3219